钙卫蛋白作为腹膜透析相关腹膜纤维化诊疗新靶点的探讨  

Investigation on calprotectin as a new target for the diagnosis and treatment of peritoneal dialyis-related peritoneal fibrosis

作　　者：阮怡霖 徐天[1] 任红[1] RUAN Yi-lin;XU Tian;REN Hong(Department of Nephrology,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China)

机构地区：[1]上海交通大学医学院附属瑞金医院肾内科,上海200025

出　　处：《中国血液净化》2023年第1期52-55,共4页Chinese Journal of Blood Purification

摘　　要：钙卫蛋白(S100A8/A9)属于S100家族中的Ca^(2+)结合蛋白,具有广泛的生物学活性,可以作为多种疾病的生物标志物。腹膜透析(peritoneal dialysis,PD)相关性腹膜纤维化(peritoneal fibrosis,PF)是PD患者中常见的并发症之一。近年来,S100A8/A9致纤维化作用也逐渐被证实,前期研究证明S100A8/A9在PF时显著上调,抑制PF后表达下降。本文主要围绕S100A8/A9作为PF诊疗新靶点的前景探讨。Calprotectin(S100A8/A9)is a Ca2+binding protein in the S100 protein family,having a wide range of biological activities and serving as a biomarker for many diseases.Peritoneal dialysis-related peritoneal fibrosis is one of the common complications in peritoneal dialysis(PD)patients.Many studies have recently proved that S100A8/A9 plays an important part in the development of peritoneal fibrosis.Our previous study also confirms that S100A8/A9 is up-regulated in peritoneal fibrosis and down-regulated after inhibition of peritoneal fibrosis.This article discusses the prospect of S100A8/A9 as a new target for the diagnosis and treatment of peritoneal fibrosis.

关 键 词：钙卫蛋白 腹膜纤维化 腹膜透析 

分 类 号：R459.5[医药卫生—治疗学]